SeaStar Medical announces presentation of new data on SCD at ASN 2024

SeaStar Medical announces the presentation of new analyses of clinical data further supporting the immunomodulating effect of the Selective Cytopheretic Device, SCD, at the American Society of Nephrology, ASN, 2024 Kidney Week to be held October 24-27 in San Diego. “We are excited to showcase these analyses at the world’s premier nephrology meeting that further describe how the SCD significantly lowered biomarkers related to inflammation in this critically ill population of patients with acute kidney injury requiring continuous kidney replacement therapy,” said Sai Prasad N. Iyer, PhD, SeaStar Medical Senior Vice President of Medical Affairs and Research. “These data further explain mechanistically how the SCD is addressing hyperinflammation and helps restore immune balance in these critically ill patients.”